Asset Details
Do you wish to reserve the book?
Mylan settles for overcharging in suit brought by EpiPen competitor
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mylan settles for overcharging in suit brought by EpiPen competitor
Do you wish to request the book?
Mylan settles for overcharging in suit brought by EpiPen competitor
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mylan settles for overcharging in suit brought by EpiPen competitor
2017
Overview
The drug company Mylan NV has agreed to pay $465m (£360m; €395m) to settle claims that it overcharged the US social healthcare program Medicaid for its anaphylaxis treatment EpiPen, a portable, single use syringe carried by patients who are at risk of life threatening allergic reactions. Sanofi will in turn give an unspecified share of its portion to another whistleblower, Ven-a-Care of the Florida Keys, a former drug infusion service that has made an estimated $280m from identifying false claims made to the US government and forcing drug companies to repay the taxpayer over $1.3bn.
Publisher
BMJ Publishing Group LTD
We currently cannot retrieve any items related to this title. Kindly check back at a later time.